长链非编码RNA FGD5-AS1在人类癌症中的表达及关键作用
Expression and crucial role of long non-coding RNA FGD5-AS1 in human cancers.
作者信息
Zhu Lixu, Shi Xiaoyi, Yu Xiao, Wang Zhihui, Zhang Menggang, He Yuting, Guo Wenzhi
机构信息
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
出版信息
Am J Transl Res. 2021 Oct 15;13(10):10964-10976. eCollection 2021.
Long non-coding RNAs (lncRNAs) are transcribed by RNA polymerase II and are longer than 200 nucleotides. Several studies have revealed that lncRNAs are important regulators of cancer progression. The lncRNA FGD5-AS1, first identified in 2018, has emerged as a crucial regulator of processes related to carcinogenesis. The expression levels of FGD5-AS1 are known to be significantly up-regulated in a variety of human cancers. Moreover, FGD5-AS1 expression closely correlates with clinical features and poor prognosis and its expression has been shown to attenuate cell proliferation, cell migration, cell invasiveness, drug resistance, and the epithelial-mesenchymal transition through several pathways. Here, we provide an overview of the role of FGD5-AS1 in various cancers and discuss its potential clinical utility in tumor progression. In addition, we used a gene expression profiling interactive analysis dataset to explore associations between FGD5-AS1 pan-cancer expressions and prognoses.
长链非编码RNA（lncRNAs）由RNA聚合酶II转录，长度超过200个核苷酸。多项研究表明，lncRNAs是癌症进展的重要调节因子。2018年首次鉴定出的lncRNA FGD5-AS1，已成为与致癌作用相关过程的关键调节因子。已知FGD5-AS1的表达水平在多种人类癌症中显著上调。此外，FGD5-AS1的表达与临床特征和不良预后密切相关，并且已表明其表达可通过多种途径减弱细胞增殖、细胞迁移、细胞侵袭、耐药性以及上皮-间质转化。在此，我们概述了FGD5-AS1在各种癌症中的作用，并讨论了其在肿瘤进展中的潜在临床应用。此外，我们使用基因表达谱交互式分析数据集来探索FGD5-AS1泛癌表达与预后之间的关联。
Zotero 插件